Watch the full interview in the video below, or read the full transcript at the bottom of the page
The science of Microdosing Semaglutide is still evolving, but its potential to revolutionize preventive health and wellness is undeniable
A few habits help quickly: Eat smaller meals: large, heavy meals tend to be harder during dose escalation Slow down at meals: many patients notice fullness earlier than they expect Keep simple notes: jot down symptoms, appetite changes, and questions for follow-up visits Dont disappear after the first prescription: ongoing review is part of safe prescribing Next-step advice: If side effects show up, dont assume you have to push through alone

To view or add a comment, sign in The GLP-1 market has moved past proof of demand. What matters now is whether your infrastructure can survive success In the last 12 months, weve seen the same pattern repeat: *Clinics grow fast *Prescribing volume increases *Regulators tighten *Fulfilment starts to wobble Thats usually when people realise their pharmacy partner was designed for small numbers - not sustained, regulated growth GLP-1s have moved on This isnt early-adopter territory anymore If your model relies on: - Manual workarounds - Fragile dispensing processes - Partners who are reacting to regulation instead of staying ahead of it it will eventually become the constraint on your growth The next phase of this market will reward operators who treat GLP-1s as infrastructure, not just medication Systems that hold under pressure will quietly outperform brands that dont Most clinics will only address this once something breaks The smart ones are doing it earlier If GLP-1s matter to your business this year, the uncomfortable question is simple: is your setup actually built to scale - or just to start

IPAMORELIN injections are a form of peptide therapy that contains the synthetic peptide known as Ipamorelin